Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
1.880
-0.120 (-6.00%)
Dec 20, 2024, 4:00 PM EST - Market closed
Intensity Therapeutics Employees
As of December 31, 2023, Intensity Therapeutics had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change
1
Growth
16.67%
Revenue / Employee
n/a
Profits / Employee
-$2,322,714
Market Cap
28.39M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7 | 1 | 16.67% |
| Dec 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Nortech Systems | 775 |
| Accelerate Diagnostics | 134 |
| Beyond Air | 107 |
| Chemomab Therapeutics | 20 |
| OneMedNet | 20 |
| Tempest Therapeutics | 17 |
| Incannex Healthcare | 9 |
| ProMIS Neurosciences | 7 |
INTS News
- 9 days ago - Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS) - PRNewsWire
- 4 weeks ago - Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - PRNewsWire
- 4 weeks ago - Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS) - PRNewsWire
- 5 weeks ago - Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 6 weeks ago - Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting - PRNewsWire
- 7 weeks ago - Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - PRNewsWire
- 3 months ago - Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - PRNewsWire
- 4 months ago - Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire